Bryan Garnier - POXEL (POXEL.PA) POXEL: Poxel serenely progresses on the road to success | CORPORATE | EUR14(+99%)

Report

Bryan Garnier

Jean-Jacques Le Fur

POXEL: Poxel serenely progresses on the road to success | CORPORATE | EUR14(+99%)

POXEL - CORPORATE | EUR14(+99%)
Poxel serenely progresses on the road to success

Twymeeg (imeglimin) approved in Japan
On the good way to confirm Phase II data for PXL 770 in NASH
Making PXL065 the second success in NASH
A need for additional cash in 2022
A valuation which underestimates NASH assets

28/06/2021 3 EN

Underlying

POXEL

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Jean-Jacques Le Fur

Other Reports on these Companies

Bryan Garnier

POXEL CORPORATE | EUR14.8 PXL065 checks histology endpoints in NASH in phase 2

º Poxel announces positive secondary endpoints after checking primary endpoint 1 month ago H1 2022 revenues below BG’s expectations Cash runway extended through at least 2023

September 21, 2022 September 21, 2022 1 EN

Bryan Garnier

POXEL CORPORATE | EUR14,8 Orphan drug designation for PXL065 & PXL770 in ALD – Need for fresh money

º Good news from the FDA for PXL065 & PXL770 Need for new funds

May 18, 2022 May 18, 2022 1 EN

Bryan Garnier

POXEL: Things are progressing well | CORPORATE | EUR14,8

POXEL - CORPORATE | EUR14,8 Things are progressing well Cash runway confirmed until H2 2022 First royalty payment from Sumitomo regarding Twymeeg Fast track designation for PXL065 in ALD – Poxel continues to be well positioned vs competitors

February 17, 2022 February 17, 2022 1 EN

Carbios and Hündgen sign a MoU for feedstock supply

This morning, Carbios announced the signing of a non-binding Memorandum of Understanding with Hündgen, a waste management expect in logistics, sorting and recycling services. The MoU concerns the supply of 15kt/year of post-consumer PET waste to be recycled in the company's first commercial plant f

11h / 43m 11h / 43m 1 EN

Paul Charpentier

Paul Charpentier

Worldline - not as weak as expected, but too early to jump in

Worldline reported 2.5% organic growth in Q1 2024, weak in absolute terms but better than anticipated by the market and us. We wait for a clear uptick in momentum and the confirmation of an improved profitability to turn positive on the stock; which is arguably far from expensive at 5.1x EV/NTM EBI

12h / 1m 12h / 1m 1 EN

Cedric Rossi

Cedric Rossi

adidas: The best sunny terrace in sporting goods currently...

During the conference call, management tried to maintain a subtle equilibrium between presenting stronger-than-expected Q1 results and tempering somewhat analysts' optimism for FY24, as evidenced by a CSS estimate (EUR1.02bn) already standing well above ADS' revised guidance of "around EUR700m". We

12h / 19m 12h / 19m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

POXEL: Poxel serenely progresses on the road to success | CORPORATE | EUR14(+99%)

POXEL CORPORATE | EUR14.8 PXL065 checks histology endpoints in NASH in phase 2

POXEL CORPORATE | EUR14,8 Orphan drug designation for PXL065 & PXL770 in ALD – Need for fresh money

POXEL: Things are progressing well | CORPORATE | EUR14,8

Carbios and Hündgen sign a MoU for feedstock supply

Worldline - not as weak as expected, but too early to jump in

adidas: The best sunny terrace in sporting goods currently...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe